LT3285772T - Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui - Google Patents

Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui

Info

Publication number
LT3285772T
LT3285772T LTEP16719356.4T LT16719356T LT3285772T LT 3285772 T LT3285772 T LT 3285772T LT 16719356 T LT16719356 T LT 16719356T LT 3285772 T LT3285772 T LT 3285772T
Authority
LT
Lithuania
Prior art keywords
sjögren
trifluoroethyl
syndrome
treatment
specific
Prior art date
Application number
LTEP16719356.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Rodger Anthony Allen
Francesca BARONE
William Anthony FAHY
Saba NAYAR
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of LT3285772T publication Critical patent/LT3285772T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP16719356.4T 2015-04-21 2016-04-20 Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui LT3285772T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (1)

Publication Number Publication Date
LT3285772T true LT3285772T (lt) 2020-01-10

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16719356.4T LT3285772T (lt) 2015-04-21 2016-04-20 Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2612862T (lt) * 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
HRP20160350T1 (hr) * 2007-03-23 2016-05-06 Amgen Inc. Heterociklički spojevi i njihove uporabe
LT2496567T (lt) * 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2667173T3 (es) * 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa

Also Published As

Publication number Publication date
IL254766B (en) 2020-05-31
AU2016251236A1 (en) 2017-11-09
EA032432B1 (ru) 2019-05-31
CY1122572T1 (el) 2021-01-27
CA2981631C (en) 2023-02-21
ES2763335T3 (es) 2020-05-28
SG11201707789YA (en) 2017-11-29
JP6721606B2 (ja) 2020-07-15
EA201792318A1 (ru) 2018-05-31
HRP20192273T1 (hr) 2020-03-06
US10493074B2 (en) 2019-12-03
EP3285772B1 (en) 2019-10-02
KR102627370B1 (ko) 2024-01-18
PL3285772T3 (pl) 2020-05-18
BR112017020591B8 (pt) 2023-05-16
CO2017010573A2 (es) 2018-03-09
KR20170140245A (ko) 2017-12-20
SI3285772T1 (sl) 2020-02-28
HUE047162T2 (hu) 2020-04-28
EP3285772A1 (en) 2018-02-28
AU2016251236B2 (en) 2018-06-14
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
MX2017013148A (es) 2018-02-21
CL2017002669A1 (es) 2018-05-11
GB201506786D0 (en) 2015-06-03
WO2016170014A1 (en) 2016-10-27
BR112017020591A2 (pt) 2018-07-03
PT3285772T (pt) 2020-01-14
US20180092921A1 (en) 2018-04-05
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20
BR112017020591B1 (pt) 2023-02-07
JP2018513862A (ja) 2018-05-31
CA2981631A1 (en) 2016-10-27
AR105552A1 (es) 2017-10-18
DK3285772T3 (da) 2020-01-13

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL247841B (en) Heterocyclic compounds in combination with immune barrier therapy for use in the treatment of disorders mediated by pi3k gamma
PT3206715T (pt) Uso de canabidiol no tratamento de complexo de esclerose tuberosa
EP3154488A4 (en) Absorbent article exhibiting controlled deformation in use
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
EP3215157B8 (en) Apilimod for use in the treatment of melanoma
IL262943A (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
GB2538923B (en) A therapeutic agent for use in the treatment of infections
EP3238600A4 (en) Adhesive cleaner for use in antibacterial treatment
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL252174A0 (en) Quinoline carboxamides for use in the treatment of leukemia
IL249402A0 (en) Aminoglycosides for the treatment of Rett's syndrome
EP3154487A4 (en) Absorbent article exhibiting controlled deformation in use
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
HUE044801T2 (hu) Adelmidrol alkalmazása epitheliális mûködési zavarok kezelésében
SG11201707789YA (en) A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome
PT3229780T (pt) Composições oftálmicas para utilização no tratamento da síndrome de olhos secos
IL247207A0 (en) Use of pericalcitol in the treatment of inflammatory anemia
GB201418541D0 (en) Materials for use with general hyperthermia treatment
ZA201408464B (en) Composition for the use in treatment of asthma
GB201407244D0 (en) Apparatus for use in the manufacture of glass items
GB201419839D0 (en) Finger dressing
GB201409978D0 (en) Novel compounds and their use in therapy
GB201416493D0 (en) Polypeptides for use in therapy